Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Core Insights - Cingulate Inc. is participating in a live event to discuss ADHD unmet needs, Phase 3 study results, and potential expansion of its PTR platform [2][5] - The company focuses on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) technology [6] Company Overview - Cingulate Inc. is a clinical-stage biopharmaceutical company headquartered in Kansas City, utilizing PTR technology to improve treatment outcomes for conditions like ADHD [6] - The company aims to identify additional therapeutic areas for its PTR technology, including anxiety disorders [6] Key Personnel - Dr. Ann Childress, a board-certified psychiatrist and scientific advisor for Cingulate, has been with the company since 2018 and has led significant clinical studies [4][7] - Dr. Childress has extensive experience in psychiatric research, having conducted over 180 clinical studies on major psychiatric drugs [7][9]